Alkem Laboratories Limited — Board Meeting, 13-11-2024: Outcome of Board Meeting

The Board has approved the standalone and consolidated unaudited financial results for the quarter and half-year ended September 30, 2024. For the standalone segment, total income was ₹29,921.6 million, with a profit after tax of ₹6,975.8 million. Consolidated results showed total income of ₹35,491.5 million, with a profit after tax of ₹7,019.6 million. Additionally, a final dividend of ₹5 per equity share has been disbursed, reflecting the company's ongoing commitment to returning value to shareholders.